Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205185) titled 'A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Soft Tissue Sarcoma (STS)
Intervention:
Drug: QL1706 + Eribulin + Anlotinib + Radiotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2025
Target Sample...